Chari Hart, MD
Cardiovascular Disease · Honolulu, HINPI 1154378701
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,860 of the $4,732 with a category attached, or 60.4%. 8 manufacturers reported payments, led by Abbott at 51.7% of the total. Reporting peaked in 2024 at $2,217 and has fallen 63.8% since, to $803 in 2025.
Across 108 payments — averaging $43.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- Edwards Lifesciences$1K
- Boston Scientific$362
- Abiomed$322
- E.r. Squibb & Sons, L.L.C.$117
- Medtronic$114
- plus $152 from 2 others
What the payments were for
- Travel & lodging$1,87240%
- Food & beverage$2,86060%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 23 | $2,448 |
| Edwards Lifesciences | 53 | $1,217 |
| Boston Scientific | 10 | $362 |
| Abiomed | 7 | $322 |
| E.r. Squibb & Sons, L.L.C. | 1 | $117 |
| Medtronic(2 entities) | 8 | $114 |
| Lantheus Medical Imaging, Inc. | 5 | $114 |
| Cvrx, Inc. | 1 | $38 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PASCAL$291
- TRICLIP$181
- MitraClip System$161
- Mitra Clip system$142
- Impella$139
- GENERAL - STRUCTURAL HEART$103
How this compares
$4,732 in reported general payments places this provider in the 70th percentile of 73 cardiovascular disease providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 92 | $118,114 |
| EntrestoSacubitril/Valsartan | 40 | $56,682 |
| XareltoRivaroxaban | 15 | $18,441 |
| FarxigaDapagliflozin Propanediol | 11 | $17,661 |
| Metoprolol Succinate | 122 | $2,851 |
| Atorvastatin Calcium | 15 | $880 |
| Rosuvastatin Calcium | 12 | $743 |
| Losartan Potassium | 24 | $493 |
| Amlodipine Besylate | 31 | $419 |
| Furosemide | 38 | $243 |
| Potassium Chloride | 11 | $189 |
| Carvedilol | 12 | $135 |
| Amoxicillin | 12 | $26 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Honolulu
- Dipanjan BanerjeeHonolulu$331K
- Joana MagnoHonolulu$23K
- Hingson ChunHonolulu$23K
- William DangHonolulu$16K
- Edward ShenHonolulu$12K
- Se Kon WonHonolulu$11K
- Wesley KaiHonolulu$10K
- Calvin WongHonolulu$8K
- Abdulelah NuqaliHonolulu$7K
- Mahdi Veillet-ChowdhuryHonolulu$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.